Geron Initiates Phase 2 Trial of GRN1005 in Brain Metastases From Breast Cancer
Great news! If Geron can get good results, it will be fast tracked. In patients with brain metastases from solid tumors, overall response rate was 20% (4/20) by one dimensional assessment when treated with a dose of 650 mg/m(2) of GRN1005 administered as single-agent therapy once every three weeks.
Good luck in this rigged casino,
No comments:
Post a Comment